P086 | ECM–DLBCL interactions drive reversible ibrutinib resistance in a 3D bone model (69 Online Views)

J. Ceccato^1|2, M. Piazza¹, G. Gualtiero^1|2, S. Carraro¹, F. Cinetto³, C. Biz⁴, M. Pizzi⁵, L. Quotti Tubi^1|2, A. Yami^1|2, J. Uddin Dekha^1|2, S. Manni^1|2, F. Piazza^1|2, A. P. Dei Tos⁵, P. Ruggieri⁵, L. Trentin¹, F. Vianello¹ | ¹Hematology Unit, Department of Medicine, University of Padua; ²Laboratory of Myeloma and Lymphoma Pathobiology, Veneto Institute of Molecular Medicine ^VIMM; ³Internal Medicine and Allergology and Clinical Immunology Units, Treviso Ca' Foncello Hospital; ⁴Surgical Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padua; ⁵Orthopedics and Orthopedic Oncology, Department of Surgery, Oncology and Gastroenterology ^DiSCOG, University-Hospital of Padova